Pediatric Parents Virtual Support Group - 2026 - May
This virtual support group is designed to support pediatric parents whose children have been diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare
Myelodysplastic Syndromes (MDS)
Caner Saygin, MD
Institution
University of Chicago
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Yael Kusne, MD PhD
Institution
Mayo Clinic, Phoenix, AZ
Physician Status
accepting new patients
Primary Disease Area of Focus
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Kidney involvement in myelodysplastic syndromes
Introduction: The objective of this study was to describe kidney involvement in patients with myelodysplastic syndromes mye
Fatigue Management
Topic(s)
Living Well with Bone Marrow Failure
Presenter(s)
Timothy Pearman, PhD
Jenny Finkel
In this webinar, Dr. Tim Pearman discusses fatigue and how it can be best managed. Jenny Finkle demonstrates some gentle exercises you can do to increase your energy level. This was an interactive session.
Post-Transplant Relapse - MDS
Topic(s)
Bone Marrow Transplant
Myelodysplastic Syndromes (MDS)
In this webinar, Dr. Alejandro Marinos Velarde discusses the risk factors that can cause post transplant relapse along with treatment and management of relapse. He answers questions from the live audience as well.
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
Background: Lenalidomide Lenalidomide: Lenalidomide is a capsule that is taken by mouth.
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for higher-risk myelodysplastic syndromes mye
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Background: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa epoetin alfa: Epoetin alfa can help improv